🔎 Trials Near Me

Beranda › Leukemia Limfositik Kronis › Georgia › Atlanta

Uji klinis Leukemia Limfositik Kronis di Atlanta, GA

11 studi untuk Leukemia Limfositik Kronis mencari peserta di lokasi sekitar Atlanta (dalam radius sekitar 30 mil). Buka studi untuk melihat kriteria peserta dan cara menghubungi tim studi.

Teks studi resmi (Bahasa Inggris)

Merekrut peserta untuk studi di sini? Tampilkan di bagian atas halaman ini — $99 selama 30 hari →

Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection

Menerima pesertaStudi observasionalSukarelawan sehat diterima
  • Atlanta VA Medical Center, Decatur · 6 mi jauhnya
Usia 40 hingga 75 · Semua jenis kelamin · Diperbarui 2 Okt 2026 · NCT05334069

A Study of Tacabrutideg (BGB-16673) Compared to Investigator's Choice in Participants With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Previously Exposed to Both Bruton Tyrosine Kinase (BTK) and B-cell Leukemia/Lymphoma 2 Protein (BCL2) Inhibitors

Menerima pesertaFase 3
  • Emory University Winship Cancer Institute, Atlanta
  • Northside Cancer Center, Atlanta
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 28 Sep 2026 · NCT06846671

Dose-escalation and Dose-expansion Study of Safety of Azer-cel (PBCAR0191) in Participants With Relapsed/Refractory (r/r) Non-Hodgkin Lymphoma (NHL) and r/r B-cell Acute Lymphoblastic Leukemia (B-ALL)

Menerima pesertaFase 1
  • Winship Cancer Institute Emory University, Atlanta
  • Northside Hospital Cancer Institute, Atlanta
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 8 Sep 2026 · NCT03666000

A Vaccine (CMV-MVA Triplex Vaccine) for the Enhancement of CMV-Specific Immunity and the Prevention of CMV Viremia in Patients Undergoing Haploidentical Hematopoietic Stem Cell Transplant

Menerima pesertaFase 1Sukarelawan sehat diterima
  • Northside Hospital, Atlanta
Usia 18 hingga 75 · Semua jenis kelamin · Diperbarui 28 Jul 2026 · NCT07020533

Evaluation of Human Immune Responses Vaccination in Patients With Lymphoma

Menerima pesertaStudi observasional
  • Emory University Hospital Midtown, Atlanta
  • Emory University Hospital/Winship Cancer Institute, Atlanta
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 6 Jul 2026 · NCT03501576

A Study of NX-5948 in Adults With Relapsed/Refractory B-cell Malignancies

Menerima pesertaFase 1
  • Winship Cancer Institute of Emory University, Atlanta
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 2 Jul 2026 · NCT05131022

CMV-MVA Triplex Vaccination in HLA-Matched Related Stem Cell Donors for the Prevention of CMV Infection in Patients Undergoing Hematopoietic Stem Cell Transplant

Menerima pesertaFase 2Sukarelawan sehat diterima
  • Northside Hospital, Atlanta
Usia 18 hingga 75 · Semua jenis kelamin · Diperbarui 10 Mar 2026 · NCT06059391

A Master Protocol to Evaluate the Long-Term Safety of (LY3527727) Pirtobrutinib

Menerima pesertaFase 4
  • The Emory Clinic, Atlanta
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 2 Mar 2026 · NCT06876649

A Study of (LY3527727) Pirtobrutinib in Participants With Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma or Non-Hodgkin Lymphoma

Menerima pesertaFase 4
  • The Emory Clinic, Atlanta
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 2 Mar 2026 · NCT06876662

Study to Assess Change in Disease Activity and Adverse Events of Oral Venetoclax With Intravenous (IV) Obinutuzumab in Adult Participants With Recurring Chronic Lymphocytic Leukemia (CLL)

Menerima pesertaFase 2
  • Winship Cancer Institute of Emory University /ID# 230643, Atlanta
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 9 Feb 2026 · NCT04895436

Phase 2 Study of Glofitamab Monotherapy & With Polatuzumab Vedotin, Pirtobrutinib, or Atezolizumab in Richter's Transformation

Menerima pesertaFase 2
  • Winship Cancer Institute at Emory University, Atlanta
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 7 Jan 2026 · NCT06043674

Uji klinis Leukemia Limfositik Kronis di kota lain

Studi lain di Atlanta

Dari ClinicalTrials.gov, data diambil 6 Okt 2026. Setiap studi menetapkan kriteria kelayakannya sendiri; tim studi yang menentukan siapa yang bisa bergabung.